))
🔒 Is your clinical trial AI racist?
Manage episode 435260646 series 3506216
Το περιεχόμενο παρέχεται από το Darshan Kulkarni. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον Darshan Kulkarni ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.
We dive into the critical issue of racial bias in AI, highlighted by a recent Yale study focusing on ChatGPT. This has significant implications for clinical research sponsors, sites, and principal investigators. We also explore the FDA's perspective on AI in clinical trials, presented by Dr. Elzarrad.
Overview of the Yale Study:
The Yale study found that ChatGPT demonstrates racial bias in its responses, raising concerns about the use of AI in clinical research. Biased AI tools can lead to skewed data and misrepresentation of minority populations in clinical trials.
Implications for Clinical Research Sponsors:
Sponsors must ensure AI tools are free from biases through thorough testing and validation. Collaboration with AI developers to refine algorithms and use diverse data sets is crucial for maintaining the integrity and fairness of clinical trials.
Implications for Clinical Sites:
Clinical sites are pivotal in implementing AI tools. Regular audits to detect and mitigate biases, along with training staff to recognize and address AI bias, ensure equitable and ethical treatment of all trial participants.
Implications for Principal Investigators:
Principal investigators must oversee the ethical conduct of trials. The discovery of bias in AI tools like ChatGPT underscores the need for transparent AI practices and the development of unbiased AI protocols.
FDA's Perspective on AI in Clinical Trials:
Dr. Elzarrad from the FDA emphasized AI's potential to revolutionize clinical trials by improving efficiency, accuracy, and patient outcomes. However, rigorous testing for biases and ethical considerations is essential, aligning with the Yale study's findings.
Role of Regulatory Bodies:
Regulatory bodies must establish comprehensive guidelines for AI use in clinical research, including mandatory bias testing and documentation. Collaboration between regulators, sponsors, and AI developers is essential for ethical AI use in clinical trials.
Subscribe for more!
126 επεισόδια
Μοίρασέ το
